MedTrace Logo

Early Follicular Supplementation of Ganirelix in IVF 2004

NCT00461422 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2008-06-27

No results posted yet for this study

Summary

Our goal was to investigate whether early follicular supplementation of the GnRH antagonist to the flexible GnRH antagonist protocol, has a potential to improve IVF-ET clinical results

Conditions

Interventions

DRUG

Ganirelix

sc injection of Ganirelix 0.25 mg per day

Sponsors & Collaborators

  • Organon

    collaborator INDUSTRY

  • The Baruch Padeh Medical Center, Poriya

    lead OTHER_GOV

Principal Investigators

  • Yohnny S Younis, MD · The Ministry of Health, Israel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Primary Completion
2007-06-30
Completion
2007-06-30

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00461422 on ClinicalTrials.gov